Skip to content
Study details
Enrolling now

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

AstraZeneca
NCT IDNCT06897930ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

150

Study length

about 4 years

Ages

18–70

Locations

14 sites in CA, FL, GA +7

What this study is about

This trial is testing a treatment called AZD0120 for adults with lupus that hasn't responded to other treatments. The goal is to see if it is safe, well-tolerated, and effective.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive AZD0120
  • 2.Take Cyclophosphamide
  • 3.Take Fludarabine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Standard assignment

Assignment is predetermined by the study protocol.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine

Drug routes

infusion

Endpoints

Primary: PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)

Secondary: PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status

Body systems

Immune